We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Quality Control Launches Acusera Anti-Müllerian Hormone (AMH) Control

By LabMedica International staff writers
Posted on 08 Jun 2022

Randox (Crumlin, UK) has launched a new Acusera Control for the accurate and reliable testing of Anti-Müllerian Hormone (AMH).

An AMH test is often used to check a woman’s ability to produce eggs that can be fertilized for pregnancy, thus helping women to make informed decisions about their health. The new Randox Acusera AMH control is designed for use as a third-party control for the quantitative determination of AMH. Available in a liquid frozen format for convenience and reduced handling errors, the control should be treated in the same manner as a patient sample.


Image: An AMH test is often used to check a woman’s ability to produce eggs that can be fertilized for pregnancy (Photo courtesy of Randox)
Image: An AMH test is often used to check a woman’s ability to produce eggs that can be fertilized for pregnancy (Photo courtesy of Randox)

The Acusera AMH is a true third-party control providing an unbiased assessment of performance and is manufactured using human serum, ensuring commutable sample matrix. It provides assayed target values, thus eliminating the need to assign values in-house. The control is available at recommended cut-off values for AMH and has 30-day stability when stored at +2°C to +8°C.

Related Links:
Randox


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit

Latest Molecular Diagnostics News

Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
08 Jun 2022  |   Molecular Diagnostics

Urine Test Diagnoses Early-Stage Prostate Cancer
08 Jun 2022  |   Molecular Diagnostics

New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
08 Jun 2022  |   Molecular Diagnostics